Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Public ClinicalTrials.gov record NCT02741570. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to compare nivolumab and ipilimumab with the extreme regimen as first line treatment in patients with recurrent or metastatic squamous cell of the head and neck cancer
Study identification
- NCT ID
- NCT02741570
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 947 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Ipilimumab Biological
- Cetuximab/Erbitux Drug
- Cisplatin/Platinol Drug
- Carboplatin/Paraplatin Drug
- Fluorouracil/Adrucil Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2016 (Actual)
- Primary completion
- May 10, 2021 (Actual)
- Completion
- Sep 22, 2022 (Actual)
- Last update posted
- Sep 21, 2023
2016 – 2022
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0134 | Tucson | Arizona | 85724-5024 | — |
| Local Institution - 0135 | Duarte | California | 91010 | — |
| Local Institution - 0005 | Stanford | California | 94305 | — |
| Local Institution - 0028 | Jacksonville | Florida | 32204 | — |
| Local Institution - 0008 | Tampa | Florida | 33612 | — |
| Local Institution - 0111 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0006 | Chicago | Illinois | 60637 | — |
| Local Institution - 0001 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0080 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0093 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0004 | Ann Arbor | Michigan | 48109 | — |
| Local Institution - 0012 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0007 | Columbus | Ohio | 43210 | — |
| Local Institution - 0010 | Langhorne | Pennsylvania | 19047 | — |
| Local Institution - 0015 | Philadelphia | Pennsylvania | 19107 | — |
| Local Institution - 0013 | Pittsburgh | Pennsylvania | 15232 | — |
| Local Institution - 0139 | Dallas | Texas | 75390 | — |
| Local Institution - 0009 | Houston | Texas | 77030 | — |
| Local Institution - 0014 | Houston | Texas | 77030 | — |
| Local Institution - 0003 | Charlottesville | Virginia | 22908 | — |
| Local Institution - 0011 | Fairfax | Virginia | 22301 | — |
| Local Institution - 0125 | Morgantown | West Virginia | 26506-9162 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 111 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02741570, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2023 · Synced Sep 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02741570 live on ClinicalTrials.gov.